

Denosumab versus zoledronic acid in breast & prostate cancer patients with bone metastasis

Health Technology Appraisal

Issued: september 2016

• بيانات المستحضر محل الدراسة:

| | |
|--------------|-----------------|
| Intervention | Denosumab |
| Trade name | Xgeva |
| Company name | Amgen |
| Comparator | Zoledronic acid |

• تاريخ عرض المستحضر:

تم تحويل المستحضر من الإجتماع المنعقد مع قطاعات الصيدلة التابعة لوزارة الصحة بتاريخ ٢٠١٦/٦/٢٩ إلي وحدة إقتصاديات الدواء لإجراء دراسة جدوي إقتصادية تقارن كلا المستحضرين zoledronic acid & denosumab في علاج solid tumors with bone metastasis

• الهدف:

- تقييم الفعالية لقاء التكلفة لمستحضر **denosumab** مقارنة بمستحضر **zoledronic acid** في علاج مرض النقائل العظمية المصاحبه لسرطان الثدي والبروستاتا وذلك لضمان أفضل النتائج العلاجية بالنسبة للمريض وبأقل تكلفة ممكنة من خلال الإلتزام بالخطوط العلاجية الاسترشادية العالمية وفي ضوء الممارسة الإكلينيكية المحلية.

- علما ان الدراسة التي قامت باجرائها وحدة اقتصاديات الدواء شملت بيانات التكلفة الخاصة بالمستحضرات والتي تم تجميعها من تسعيرة الادارة الفنية لمناقصات الادوية ومناقصات مستشفيات وزاره الصحة ، بالاضافة إلى باقي التكلفة المرتبطة بالإقامة بالمستشفى والأدوية والتبغات المحتملة عن علاج حالات الكسر بأنواعها والنتيجة عن استخدام كل بروتوكول على حدة، وطبقا لتسعيرة نفقة الدولة .

- تم تجميع البيانات الخاصة بالقيمة العلاجية الناتجة عن جودة الحياة المعيشية للمريض "QUALITY OF LIFE" ونسبة الحالات المستجيبة للعلاج من الدراسات المنشورة عالميًا .

قرار اللجنة:

- أظهرت النتائج ان مستحضر Denosumab عند سعر ٢٤٠٠ جنيه ليس هو الأكفء من حيث الفعالية لقاء التكلفة "not cost effective" بالمقارنة بمستحضر Zoledronic acid عند سعر ٩٨٠ جنيه في كلا من مرضي **breast and prostate cancer** .

- وذلك علي الرغم من تفوق مستحضر Denosumab في تحسين جودة الحياة المعيشية بفارق 0.028QALY و 0.3QALY لمرضي

مرضي سرطان الثدي ومرضي سرطان البروستاتا علي التوالي وذلك بسبب أفضليته في تأخير الوقت لحدوث skeletal related events والتي تعتبر the primary endpoints بفارق 3.6 شهر لصالح مستحضر Denosumab .

- كما أنه يوجد فرق في التكلفة بين المستحضرين لصالح مستحضر Zoledronic acid الذي يعتبر الأرخص في كلا من مرضي سرطان الثدي ومرضي سرطان البروستاتا بنحو ٤٠٠٢٨ جنيه و ٤٠٤٠٥ جنيه علي التوالي. وذلك نظرا لأنه يتم تقليل مرات إعطائه من كل شهر إلي كل ثلاثة أشهر مع الحفاظ علي نفس الفعالية العلاجية خلال العام الثاني من العلاج.

- وبمراجعة قواعد العلاج الاسترشادية في هذا الغرض العلاجي تبين ان نسبة حدوث osteonecrosis of the jaw كأثر جانبي من كلا المستحضرين تزداد بعد سنتين من بدء العلاج لذا يتم إيقافه بعد تلك المدة وعليه تم إجراء الدراسة وحساب التكلفة والفعاليه علي مدار سنتين فقط. كما أوصي المتخصصين بقصر استخدام denosumab لمرضي الكلي حيث يمنع استخدام zoledronic acid في هذه الفئة من المرضي وذلك لما ينتج عنه من مشاكل وأضرار جانبية للكلي.

- جدير بالإشارة ان الدراسة لم تتضمن مستحضر Clodronate وذلك بعد إفادة المتخصصين في المجال بعدم استخدامه ضمن بروتوكولات العلاج لمرضي multiple myeloma and patients with bone metastases from solid tumors نظرا لوجود اشتراطات وقيود علي الأمان والفعالية.

English Summary:

Cost-effectiveness of denosumab versus zoledronic acid in the treatment of breast and prostate cancer Patients with bone metastasis: Adecision tree Model

Introduction:

Patients with advanced solid tumors commonly develop bone metastases. Bone metastases cause bone destruction through increased osteoclast activity, frequently resulting in skeletal complications known as skeletal-related events (SREs; commonly defined as pathologic fracture, radiation to bone, surgery to bone and spinal cord compression). SREs are associated with significant and debilitating pain, impaired morbidity, reduced quality of life, substantial health-resource utilisation and associated costs.

Bisphosphonates are bone targeted agents that have been historically used to reduce the risk of SREs in patients with bone metastases. Zoledronic acid has been considered the standard of care and has been shown to prolong time to first SRE and reduce the number of SREs; however, many patients with bone metastases continue to experience SREs. ZA is infused intravenously (IV) every 3–4 weeks and is associated with renal toxicity (1).

Denosumab has a different and novel mode of action; it is the first fully human monoclonal IgG2 antibody that binds to RANK ligand. RANK ligand is an essential mediator of the formation, activation and survival of osteoclasts.

Denosumab (120 mg subcutaneous injection (SC) every 4 weeks) was compared with ZA (4 mg IV every 4 weeks) in three identically designed phase III head to head clinical trials of patients with bone metastases from solid tumours (breast cancer, prostate cancer and other solid tumours or multiple myeloma). Denosumab does not require renal monitoring. The overall incidence of adverse events was similar between denosumab and Zoledronic acid (2, 3).

Objective:

To evaluate the cost- effectiveness of denosumab versus zoledronic acid in breast and prostate cancer with bone metastasis from health insurance perspective

• **Economic evaluation Key Features (4)**

| Key Features: | |
|---|---|
| year of the document | September 2016 |
| Affiliation of authors | Pharmacoeconomic Unit, Central Administration for Pharmaceutical Affairs |
| Purpose of the document | Evaluation the cost-effectiveness of using denosumab versus zoledronic acid in the treatment of breast and prostate cancer patients with bone metastasis. |
| Standard reporting format included | yes |
| Disclosure | yes |
| Target audience of funding/ author's interests | Public and private payers, healthcare industries and clinicians |
| Perspective | Ministry of health perspective |
| Indication | Treatment of breast and prostate cancer with bone metastasis. |

| | |
|---|---|
| Target population | Those who insured by the Egyptian health care system |
| Subgroup analysis | No subgroup analysis was done. |
| Choice of comparator | Zoledronic acid |
| Time horizon | Decision tree over one-year as a base case and over 2-years as another scenario representing the clinical practice. |
| Assumptions required | yes |
| Analytical technique | Cost-effectiveness analysis |
| Costs to be included | Total costs include costs of treatment and managing strategies according to the Egyptian current practice. |
| Source of costs | Official sources of unit cost data for products (e.g. Tender lists) and MOH hospitals. |
| Modeling | Decision tree model |
| Systematic review of evidences | yes |
| Preference for effectiveness over efficacy | yes |
| Outcome measure | The outcomes of the two treatments were measured in terms of quality-adjusted life-years (QALYs) |
| Method to derive utility | Utility taken from published study used Time trade off method (TTO) to calculate utility. |
| Equity issues stated | All lives, life years, or QALYs are valued equally, regardless of age, gender, or socioeconomic status of individuals in the population |
| Discounting costs | Not applicable. |
| Discounting outcomes | Not applicable. |
| Sensitivity analysis-parameters and range | Critical component(s) in the calculation is varied through a relevant range or from worst case to best case. |
| Sensitivity analysis-methods | One-way sensitivity analysis is performed. |
| Presenting results | Denosumab is not cost-effective compared to zoledronic acid in management of breast and prostate cancer patients with bone metastasis. |
| Incremental analysis | yes |
| Total costs vs. effectiveness (cost/effectiveness ratio) | yes |
| Portability of results (Generalizability) | The generalizability and extent to which the clinical efficacy data and the economic data are representative is discussed. |

Committee Discussion:

Due to the novel mode of action of denosumab and the need for it in patients with renal problems who can't tolerate zoledronic acid, it is important to evaluate its efficacy and impact on the quality of life of the patients. So the main objective of this economic evaluation study is to evaluate the cost effectiveness of denosumab versus zoledronic acid in patients with bone metastasis from breast and prostate cancer.

A comprehensive search of PubMed and MEDLINE was conducted for English articles published to retrieve the available published data regarding Randomized controlled Trials (RCTs), systematic reviews, and meta-analyses of RCTs. because they provide the least biased and most robust evidence regarding treatment. All indirect clinical trials were excluded; only head to head clinical studies comparing denosumab with zoledronic acid in the target indication are included in the economic study.

The clinical parameters in breast cancer patients were derived from head to head, randomized, double-blind, double-dummy, active controlled study compared denosumab with zoledronic acid for the treatment of bone metastases in breast cancer patients involved 322 centers in Europe, North America, South America, Japan, Australia, India, and South Africa. 2,046 Patients were randomly assigned to receive either a subcutaneous injection of denosumab 120 mg and an intravenous infusion of placebo every 4 weeks or an intravenous infusion (lasting no less than 15 minutes) of zoledronic acid 4 mg and a subcutaneous injection of placebo every 4 weeks. The primary end point was time to first on-study skeletal-related event (non-inferiority test). [5], The clinical parameters in prostate cancer patients were derived from a phase 3 randomized multicenter study which enrolled patients from 342 centres in 39 countries worldwide. 1904 patients were enrolled in the study of which 951 patients assigned to receive zoledronic acid (I.V) 4mg and 950 patients assigned to receive denosumab (S.C) 120 mg. The primary endpoint was time to first on-study skeletal-related event, and was assessed for non-inferiority. [6]

Utility values were derived from a previously published clinical study which involved 187 participants of the general population. The draft health states were administered in a TTO interview to ensure that respondents were able to understand the health states and the interview task, a 2-year time frame was used in this study so that the impact of the SREs would be judged within the context of a realistic life expectancy for a patient with advanced cancer and bone metastases [7]. Disutility caused by the duration of infusion in case of zoledronic acid and by subcutaneous injection in case of denosumab was taken from another study involved 121 participants from UK and time trade off method was used. [8]

Direct medical costs regarding cost of treatment, monitoring test performed and cost of management of side effects were obtained from the Ministry of health hospitals in Egypt.

The results of the cost effectiveness study revealed that denosumab isn't cost effective compared to zoledronic acid in both breast and prostate cancer with bone metastasis with an ICER of 1,4238,07

EGP/QALY in breast cancer and an ICER of 134,593 EGP/QALY in prostate cancer over a two- year time horizon decision tree model.

This result wasn't comparable with the results of a cost -effectiveness study performed in United States which compared denosumab versus zoledronic acid in bone metastasis from solid tumors. The study conclusion was that denosumab is a cost-effective treatment option for the prevention of SREs in patients with advanced solid tumors and bone metastases compared to ZA. The overall value of denosumab is based on superior efficacy, favorable safety, and more efficient administration. [9]


But the result in our model was comparable with an economic evaluation study comparing both interventions in hormone refractory prostate cancer patients with bone metastasis which concluded that although denosumab has demonstrated benefits over zoledronic acid in preventing or delaying SREs in a phase 3 trial, it may be a costly alternative to zoledronic acid from a U.S. payer perspective [10]. **And also comparable with another** economic study, comparing the two interventions in breast cancer patients with bone metastasis in United States. It concluded that although denosumab demonstrated superiority in preventing SREs in the phase III trial, it may not be cost-effective compared with zoledronic acid because of its high cost.[11]

The limitation of this economic study seems to be represented by short time horizon which is over a 2 years only but according to recently published guidelines and expert opinion the risk of jaw osteonecrosis appears to be related to time on bone-targeted therapy and since it happens treatment should be stopped; therefore caution should be taken in using these agents more than 2 years. And for this reason we measured outcomes and costs in our model over 2-years only. [12]

This economic evaluation was a cost-utility assessment that compared projected costs and outcomes of two alternative treatment options on the basis of trial results from healthcare perspective. The cost per QALY is a useful measure, as the ratio is not disease-specific and can be compared across a spectrum of therapeutic interventions. Cost-utility analyses are, thus, the preferred type of economic evaluation and this is the main strength point of the study.

As in all modeling exercises, several assumptions were made in this study leading to uncertainties in the results. In this analysis, we explicitly accounted for these uncertainties by assigning confidence intervals and plausibility ranges based on published sources to the quality-of-life, skeletal related events probabilities, and monitoring costs in the model. Robustness of results was assessed by using sensitivity analysis. One way sensitivity analysis was conducted and illustrated that the key factor which has the greatest impact on the result in breast cancer indication is the 2-year probability of SRE in zoledronic acid arm while the key driver in prostate cancer indication is the cost of denosumab.

Figure 1: illustrating the decision tree model of the cost effectiveness study



SRE: skeletal related events.

- **Conclusion**

It is important to address both the clinical and the economic implications of a new therapy from the payer perspective before deciding on public reimbursement of new therapies. Taking the above-mentioned limitations and uncertainties in consideration the conclusion is that denosumab is not cost-effective versus zoledronic acid in both breast and prostate cancer patients with bone metastasis from Ministry of health perspective.

- **Declaration of interest**

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

- **Appraisal Committee members**

Each technology appraisal is appraised by the PE Committee, which is one of CAPA's standing advisory committees and consist of members who represent different specialties such as statistics, clinical evidence, economics, medicine, clinical pharmacy and pharmacoeconomics. A list of the Committee members who took part in the discussions for this appraisal appears below:

Dr. Gihan Hamdy, Head of Pharmacoeconomic Unit, Central Administration for Pharmaceutical Affairs, Ministry of Health.

Dr. Randa El dessouki, Assistant lecturer, faculty of medicine, Fayoum University

Prof. Ahmed Hassouna, Consultant of clinical trials & Professor of Cardiology, Faculty of Medicine, Ain Shams University.

Dr. Nirmeen Ashoush, lecturer health economics in British university in Cairo.

Dr. Souad Abd Al Aleem, Manager of Hospital Pharmacy Administration, Central Administration for Pharmaceutical Affairs, Ministry of Health

Dr Makram Atef , Associate Minister of Health.

• **PEU project team**

- **Gihan Hamdy El-sisi**, Head of Pharmacoeconomic Unit, Central Administration for Pharmaceutical Affairs, Ministry of Health.
- **Asmaa Saad**, Team member of Pharmacoeconomic Unit, Central Administration for Pharmaceutical Affairs, Ministry of Health.

References:

- 1-Oglesby A, Sherif B, Odom D, et al.** Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. *Commun Oncol* 2009;6:494–50
- 2-Stopeck AT, Lipton A, Body JJ, et al.** Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol* 2010;28:5132–9.
- 3-Henry D, Von Moos R, Hungria V, et al.** Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer. *J Clin Oncol* 2010;28(7s):abstract 9133.
- 4-Elsisi G, Kaló Z, Eldessouki R, et al;** Guidelines for reporting pharmacoeconomic evaluations in Egypt; *Value in Health Regional Issues*; Volume 2, Issue 2, September–October 2013, Pages 319–327.
- 5- Alison T. Stopeck, Allan Lipton** Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study *J Clin Oncol* 28:5132-5139 DOI: 10.1200/JCO.2010.29.7101

- 6- **Karim Fizazi, Michael Carducci** Denosumab versus zoledronic acid for treatment of bone metastases in men with castration resistant prostate cancer: a randomised, double-blind study *Lancet*. 2011 March 5; 377(9768): 813–822. doi:10.1016/S0140-6736(10)62344-6.
- 7- **Louis S Matza** Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases *Patient Preference and Adherence* 2013;7 855–865
- 8- **Louis S. Matza , Karen Chung** Health state utilities for skeletal-related events secondary to bone metastases *Eur J Health Econ* (2014) 15:7–18 DOI 10.1007/s10198-012-0443-2
- 9- **Stopeck A¹, Rader M, Henry D** Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. *J Med Econ*. 2012;15(4):712-23. doi: 10.3111/13696998.2012.675380. Epub 2012 Mar 27.
- 10- **Xie J¹, Namjoshi M** Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. *J Manag Care Pharm*. 2011 Oct;17(8):621-43.
- 11- **Xie J¹, Diener M, Sorg R** Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases. *Clin Breast Cancer*. 2012 Aug;12(4):247-58. doi: 10.1016/j.clbc.2012.04.001. Epub 2012 Jun 12.
- 12- **Fred Saad, MD, FRCSC;* Kim N. Chi, MD** The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC) *Can Urol Assoc J* 2015;9(3-4):90-6.
<http://dx.doi.org/10.5489/cuaj.2526>